Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 28, 2025

Stock market today: S&P 500, Dow rise to end a rocky month, Nasdaq snaps 7-month win streak

View original at finance.yahoo.com
Stock market today: S&P 500, Dow rise to end a rocky month, Nasdaq snaps 7-month win streak US stocks rose during a holiday-shortened trading day on Friday as a volatile month drew to a close and the Nasdaq Composite (^IXIC) snapped a seven-month win streak…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • S&P 500 will hover around 7,500 by end of 2026

    80% confidence
  • S&P 500 will reach 8,000 by end of 2026

    80% confidence
  • Government has tremendous deficit, tremendous government spending, and tremendous central bank buying supporting gold prices

    80% confidence
  • Expects Black Friday to kick off a strong holiday shopping season with consumers spending $253 billion

    80% confidence
  • Companies missing Q3 earnings estimates saw stock decrease of 5% on average, well below five-year average decrease of 2.6%

    80% confidence
  • Consumers spent $6 billion on Thanksgiving Day

    80% confidence
  • S&P 500 will hover around 7,500 by end of 2026

    80% confidence
  • S&P 500 companies reporting Q3 earnings beats saw stock price increase of 0.4% on average in four-day period around earnings release, below five-year average of 0.9%

    80% confidence
  • Oracle faces credit market concerns that will worsen in 2026 unless Oracle can reassure investors about AI spending

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com